In 1999, defendants settled a nationwide class action involving certain diet drugs. With limited exceptions, the settlement contained an injunction against members of the class suing defendants for injuries related to those drugs. In re Diet Drugs Product Liability Litigation, 706 F.3d 217 (3d Cir. 2013) (No. 12-1180), addresses the scope of this injunction. New plaintiffs filed an action for injuries resulting from the diet drugs. Defendants moved to enjoin the lawsuit for failure to fall within the limited category of lawsuits the settlement did not enjoin. The district court agreed with defendants, and enjoined the lawsuit. On appeal, the court of appeals affirmed and held the district court was correct in its interpretation of the settlement agreement and in finding that plaintiffs did not satisfy its exception. The court also declined to reform the settlement agreement to reflect developments in scientific knowledge, finding this argument had been waived – it was not sufficiently raised below – and a complete factual record on the relevant scientific changes in technology and procedures was essential to this argument.